Back

Implementation of prasugrel and prognostic outcomes after percutaneous coronary intervention for myocardial infarction: a nationwide observational study

30 August 2024 (12:20 - 12:30)
Organised by: Logo
Congress Presentation Part of: Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mia Ravn Jacobsen

Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention - a nationwide population-based study
Mr J. Cho (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry
Doctor F. Giacobbe (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Pretreatment with dual antiplatelet therapy in acute myocardial infarction
Professor Z. Motovska (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Cangrelor versus no cangrelor during percutaneous coronary intervention in hemodynamically unstable patients: a cohort study on benefits and risks
Mr O. Emilsson (Lund, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 12:20 CET
You may be interested in
thumbnail
Congress Session
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
thumbnail
Congress Presentation
Ticagrelor or prasugrel versus clopidogrel in patients with coronary heart disease
thumbnail
Congress Presentation
Is prasugrel preferred over ticagrelor?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources